Literature DB >> 3121328

Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator.

G Pohl1, L Kenne, B Nilsson, M Einarsson.   

Abstract

Electrophoretic analysis of endoglycosidase-treated tissue plasminogen activator obtained from human melanoma cells showed that the heterogeneity observed for the protein in these preparations is caused by an N-glycosidically linked N-acetyllactosamine type of carbohydrate chain which is present in about 50% of the molecules. An oligomannose type and an N-acetyllactosamine type of glycan is present in all molecules. Three glycopeptides were isolated and characterized by 1H-NMR, sugar determination, methylation analysis and amino acid determination. The exact attachment site for each of the three glycans could be deduced from the amino acid compositions of the glycopeptides. Asn-117 carries the oligomannose type of glycan, the structure of which was completely determined. Asn-184 is the site where the presence or absence of a biantennary N-acetyllactosamine type of glycan causes the size heterogeneity. The third N-glycosylation site, Asn-448, was found to carry a triantennary or tetraantennary N-acetyllactosamine type of carbohydrate chain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121328     DOI: 10.1111/j.1432-1033.1987.tb13668.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

1.  Separation and characterization of the two Asn-linked glycosylation sites of chicken serum riboflavin-binding protein. Glycosylation differences despite similarity of primary structure.

Authors:  J S Rohrer; H B White
Journal:  Biochem J       Date:  1992-07-01       Impact factor: 3.857

2.  Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.

Authors:  U Martin; S Fischer; U Kohnert; U Opitz; R Rudolph; G Sponer; A Stern; K Strein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

3.  The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycans.

Authors:  A J Jaques; G Opdenakker; T W Rademacher; R A Dwek; S E Zamze
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

4.  Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.

Authors:  M Otter; J Kuiper; R Bos; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

5.  alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.

Authors:  K A Hajjar; C M Reynolds
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

6.  Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.

Authors:  J Kuiper; A Van't Hof; M Otter; E A Biessen; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

7.  Tissue plasminogen activator is a ligand of cation-independent mannose 6-phosphate receptor and consists of glycoforms that contain mannose 6-phosphate.

Authors:  James J Miller; Richard N Bohnsack; Linda J Olson; Mayumi Ishihara; Kazuhiro Aoki; Michael Tiemeyer; Nancy M Dahms
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

8.  Clearance function of scavenger endothelial cells.

Authors:  Bård Smedsrød
Journal:  Comp Hepatol       Date:  2004-01-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.